How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
2026-10-11 02:15
•Reuben Gregg Brewer •The Motley Fool
••••• •••••• Axe Cap view
Pharma Dividends: A Mixed Bag for Steady Income
Balancing yield and risk in big pharma stocks is essential—don’t chase high dividends without diversification.
South African investors looking at pharma for dividend income should tread carefully. Pfizer’s 6%+ yield looks tempting, but its dividend isn’t fully covered by earnings and the pipeline is weak, risking cuts. Johnson & Johnson and AbbVie, by contrast, offer steady growth and resilience with their broad product portfolios and strong dividend track records, though yields hover around 2-2.5%. Bristol Myers Squibb and Celgene add moderate yield but carry patent expiry risks, which could pressure dividends down the line. Amgen stands out with a longer patent runway and pipeline diversity, but biosimilar threats linger. Given the rand’s recent steadiness against the dollar, income in USD can add attractive diversification to a local portfolio. However, SA investors should avoid overconcentration in any single name here. The biggest danger is overpaying for yield while ignoring looming patent cliffs. A diversified approach across JSE banks or consumer shares may offer more reliable income and less binary risk. this is just our opinion and not financial advice
Trim exposure to Pfizer and Bristol Myers Squibb, watch for dividend stability in Johnson & Johnson and AbbVie, and consider adding Amgen for growth. Avoid chasing yield at the cost of dividend safety.
- USD/ZAR
- JNJ
- ABBV
- AMGN
- Patent expiration leading to dividend cuts
- Biotech pipeline execution failures
6/10
To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.
Our take is based on reporting first published by The Motley Fool.